Search Results for keywords:"public advisory committee meeting"

The Food and Drug Administration (FDA) is holding a virtual public advisory committee meeting on February 20, 2025. The meeting will involve discussions on the benefits and risks of using dermal fillers, including new uses such as for the decolletage area. The FDA has opened a public comment period for this meeting, with comments due by March 20, 2025. Public comments submitted by January 30, 2025, will be shared with the Committee, and the public can participate by submitting comments or making presentations during the meeting.

The Food and Drug Administration (FDA) is announcing a public advisory committee meeting involving the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. This meeting, which will be held online due to COVID-19, is set for March 24-25, 2021. During the meeting, the committees will discuss a drug application by Pfizer for a treatment targeting moderate to severe osteoarthritis. The FDA has established a public docket to gather comments on regulatory issues, which will remain open until March 23, 2021.

The Food and Drug Administration (FDA) is announcing a public advisory committee meeting for the Cellular, Tissue, and Gene Therapies Advisory Committee on April 15, 2021. This meeting, which will be held online due to the COVID-19 pandemic, aims to discuss scientific issues such as biologics license applications. The public can submit comments electronically or on paper until April 14, 2021. The FDA encourages public participation and will provide online access to the meeting materials two days before the event.

The Food and Drug Administration (FDA) is announcing a public advisory committee meeting for the Vaccines and Related Biological Products Advisory Committee. The committee will discuss and provide recommendations regarding the strains to be included in the influenza vaccines for the 2021-2022 flu season. The meeting will be held online on March 5, 2021, from 9 a.m. to 3:30 p.m. Eastern Time, due to the COVID-19 pandemic. Public comments can be submitted until March 4, 2021, and those received by February 24 will be shared with the committee before the meeting.

The Food and Drug Administration (FDA) is hosting a joint public advisory committee meeting on February 5, 2025. This meeting involves the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. The focus will be on discussing the outcomes of studies related to the risks associated with long-term use of extended-release/long-acting opioid analgesics. The FDA has opened a public comment docket, which will close on February 4, 2025, allowing individuals to submit their views electronically or by mail.

The Food and Drug Administration (FDA) announced a public advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting, scheduled for January 10, 2025, is open to the public and can be attended either in person at the FDA campus in Silver Spring, MD, or online. The meeting will discuss the Biologics License Application for condoliase injection, aimed at treating radicular leg pain associated with lumbar disc herniation. The FDA is also accepting public comments on this topic until January 9, 2025, and encourages individuals to submit their views electronically or via written submissions.